Refractory Myasthenia Gravis and Concurrent Alopecia Areata Postthymectomy With Improvements After Cortisone Taper: A Case Report

TL;DR

A 58-year-old man with severe myasthenia gravis and alopecia areata showed improvement after cortisone tapering, suggesting a link between these autoimmune conditions.

Contribution

Demonstrates a novel therapeutic approach using cortisone tapering for refractory myasthenia gravis and concurrent alopecia areata.

Findings

Significant clinical improvement observed after cortisone tapering in a patient with refractory myasthenia gravis.

Alopecia areata developed postthymectomy, suggesting a possible immunological link between the two autoimmune conditions.

Abstract

This case report presents a unique clinical scenario of a 58-year-old male suffering from severe refractory myasthenia gravis and concurrent alopecia areata postthymectomy. Myasthenia gravis, a common autoimmune disorder, is characterized by muscle weakness due to autoantibodies targeting neuromuscular junction proteins. Alopecia areata, another autoimmune disease, is often seen in individuals with myasthenia gravis, suggesting a shared immunological basis. The patient's condition was resistant to conventional treatment, and he developed alopecia areata following thymectomy. Despite the challenges in managing refractory myasthenia gravis and the associated alopecia areata, significant improvements were observed following a cortisone taper. This case highlights the potential therapeutic role of cortisone tapering in managing refractory myasthenia gravis and associated alopecia areata. This case also prompts further exploration into the immunological shifts following thymectomy, particularly its potential role in triggering alopecia areata.

Figures